Helping patients with rare genetic disorders of obesity

The Genetic Obesity Project is dedicated to improving the understanding, diagnosis, and treatment of severe obesity that is caused by specific genetic defects—particularly rare genetic disorders that result in life-threatening obesity.

POMC-deficiency-obesity

Patient Stories

Single genetic defects along the MC4 pathway that result in early-onset and severe obesity are now identified.
 
Healthcare Professionals:

Join the Project

The Genetic Obesity Project has initiated a Genotyping Study and a Patient Registry for POMC deficiency obesity and LEPR deficiency obesity.
Interested in The Genetic Obesity Project?
Stay informed about our latest developments and projects.
This program is supported by Rhythm, a Boston-based biopharmaceutical company developing the MC4R peptide agonist, setmelanotide (RM-493), for obesity caused by genetic deficiencies in the MC4 pathway.